Abigail Powell

Jul 1, 2024 | biorxiv.org | Abigail Powell |Soyoon Park |Jui-Lin Chen |Hannah Caruso

AbstractMiddle East respiratory syndrome coronavirus (MERS-CoV) was first identified as a human pathogenic virus in 2012 and is causing ongoing sporadic infections as well as outbreak clusters. Despite case fatality rates (CFRs) of over 30% and the pandemic potential associated with betacoronaviruses, a safe and efficacious vaccine has not been developed for prevention of MERS in at-risk individuals.

Oct 17, 2023 | biorxiv.org | Duo Xu |Abigail Powell |Mrinmoy Sanyal |Ashley Utz

AbstractEbola virus causes hemorrhagic fever in humans and poses a significant threat to global public health. Although two viral vector vaccines have been approved to prevent Ebola virus disease, they are distributed in the limited ring vaccination setting and only indicated for prevention of infection from orthoebolavirus zairense (EBOV) - one of three orthoebolavirus species that have caused previous outbreaks.

Oct 6, 2023 | dx.doi.org | Ben S Ou |Julie Baillet |Emily Gale |Abigail Powell

Vaccines are among the most effective medical advancements in history and are estimated to save 2.5 million lives worldwide annually. (1) Unfortunately, an abundance of infectious diseases, including many rapidly mutating viral pathogens such as HIV, influenza, and SARS-CoV-2,still do not have sufficiently effective vaccines capable of providing broad and durable protection for a global population.